By targeting the PD-1 pathway with a PD-1 inhibitor and HPK1 with an HPK1 inhibitor, the chance of broadening the immune response against cancer cells increases, potentially improving treatment outcomes. The gene discussed is MAP4K1; the disease is cancer.